MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: Aug 7, 2025
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected in the Fourth Quarter of 2025
Read more at prnewswire.com
